Long-Term Disease Control with Triapine-Based Radiochemotherapy for Patients with Stage IB2–IIIB Cervical Cancer

Background: National Cancer Institute phase I #7336 and phase II #8327 clinical trials explored the safety and efficacy of triapine (NSC #663249) added to cisplatin radiochemotherapy in untreated patients with advanced-stage cervical cancer. Triapine inhibits ribonucleotide reductase, the rate-limit...

Descripción completa

Detalles Bibliográficos
Autores principales: Kunos, Charles A., Sherertz, Tracy M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2014
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4109518/
https://www.ncbi.nlm.nih.gov/pubmed/25105092
http://dx.doi.org/10.3389/fonc.2014.00184

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4109518/
https://www.ncbi.nlm.nih.gov/pubmed/25105092
http://dx.doi.org/10.3389/fonc.2014.00184

Ejemplares similares